Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Georgina Dall"'
1
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics
Autor: Georgina Dall, Richard E. Nelson, David Bin-Chia Wu, Mohamed A. Kamal, Carl M. J. Kirkpatrick, Aaron W. C. Kamauu, Craig R Rayner, Kenneth K.C. Lee, Nathorn Chaiyakunapruk, Stephen Toovey, Chayanin Pratoomsoot, Keith Nieforth, David C. M. Kong, Huey Yi Chong, Patrick F. Smith
Publikováno v: British Journal of Clinical Pharmacology. 83:1580-1594
Aims A modular interdisciplinary platform was developed to investigate the economic impact of oseltamivir treatment by dosage regimen under simulated influenza pandemic scenarios. Methods The pharmacology module consisted of a pharmacokinetic distrib
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3aff16c78509adda51abf9b986d817fe
https://doi.org/10.1111/bcp.13229
Zobrazit plný text záznamu
2
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects
Autor: Peter N. Morcos, Meret Martin-Facklam, Carolina Sturm, Ali Zeaiter, Neil Parrott, Elena Guerini, Alex Phipps, Katrijn Bogman, Georgina Dall, Ludger Banken, Marc Lindenberg, Carsten Timpe
Publikováno v: Clinical Pharmacology in Drug Development. 6:266-279
The anaplastic lymphoma kinase (ALK) inhibitor alectinib is an effective treatment for ALK-positive non-small-cell lung cancer. This bioequivalence study evaluated the in vivo performance of test 3 formulations with the reduced wetting agent sodium l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c89f6d12c958b6943616b083e944972
https://doi.org/10.1002/cpdd.299
Zobrazit plný text záznamu
3
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects
Autor: Elena Guerini, Steven Blotner, Bogdana Balas, Meret Martin-Facklam, Carolina Sturm, Peter N. Morcos, Alex Phipps, Katrijn Bogman, Georgina Dall, Neil Parrott
Publikováno v: Clinical Pharmacology in Drug Development. 6:388-397
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, is approved for treatment of patients with ALK+ non-small cell lung cancer who have progressed, on or are intolerant to, crizotinib. This study assessed the effect of a high-fat meal and the p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b41faf77a9ea051122d3c973007a0f6a
https://doi.org/10.1002/cpdd.296
Zobrazit plný text záznamu
5
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects
Autor: Peter N, Morcos, Elena, Guerini, Neil, Parrott, Georgina, Dall, Steven, Blotner, Katrijn, Bogman, Carolina, Sturm, Bogdana, Balas, Meret, Martin-Facklam, Alex, Phipps
Publikováno v: Clinical pharmacology in drug development. 6(4)
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, is approved for treatment of patients with ALK+ non-small cell lung cancer who have progressed, on or are intolerant to, crizotinib. This study assessed the effect of a high-fat meal and the p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4070ec12c2cc8d75bff5525f9aa27795
https://pubmed.ncbi.nlm.nih.gov/27545320
Zobrazit plný text záznamu
6
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
Autor: Li Yu, Luigi De Petris, Meret Martin-Facklam, Yumi Cleary, Peter N. Morcos, Alex Phipps, Santiago Viteri, Walter Bordogna, Elena Guerini, Katrijn Bogman, Georgina Dall
Publikováno v: Clinical pharmacology in drug development. 6(3)
The efficacy and safety of alectinib, a central nervous system-active and selective anaplastic lymphoma kinase (ALK) inhibitor, has been demonstrated in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) progressing on crizotinib. A
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad36d7126875c1d2a23a0a7b27cb9135
https://pubmed.ncbi.nlm.nih.gov/27545757
Zobrazit plný text záznamu
7
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects
Autor: Peter N, Morcos, Neil, Parrott, Ludger, Banken, Carsten, Timpe, Marc, Lindenberg, Elena, Guerini, Georgina, Dall, Katrijn, Bogman, Carolina, Sturm, Ali, Zeaiter, Meret, Martin-Facklam, Alex, Phipps
Publikováno v: Clinical pharmacology in drug development. 6(3)
The anaplastic lymphoma kinase (ALK) inhibitor alectinib is an effective treatment for ALK-positive non-small-cell lung cancer. This bioequivalence study evaluated the in vivo performance of test 3 formulations with the reduced wetting agent sodium l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::97fc2e1a79a1474d921f286489930c7d
https://pubmed.ncbi.nlm.nih.gov/27545871
Zobrazit plný text záznamu
8
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics
Autor: Mohamed A, Kamal, Patrick F, Smith, Nathorn, Chaiyakunapruk, David B C, Wu, Chayanin, Pratoomsoot, Kenneth K C, Lee, Huey Yi, Chong, Richard E, Nelson, Keith, Nieforth, Georgina, Dall, Stephen, Toovey, David C M, Kong, Aaron, Kamauu, Carl M, Kirkpatrick, Craig R, Rayner
Publikováno v: British journal of clinical pharmacology. 83(7)
A modular interdisciplinary platform was developed to investigate the economic impact of oseltamivir treatment by dosage regimen under simulated influenza pandemic scenarios.The pharmacology module consisted of a pharmacokinetic distribution of oselt
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b396e144c09caa595febd5cb1d8ddd80
https://pubmed.ncbi.nlm.nih.gov/28176362
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje